Concepedia

Niranjan Y. Sardesai

NY

111

Publications

6.6K

Citations

46

H-Index

1994

Active since

Affiliations

Inovio Pharmaceuticals (United States)(Current)

University of Pennsylvania

The Wistar Institute

Frederick National Laboratory for Cancer Research

Center for Cancer Research

Niranjan Y. Sardesai is an author at Inovio Pharmaceuticals (United States) specializing in vaccination, immunology, and medicine.

ORCID

Top concepts

Publications per year

1994–2024

111

Publications

111

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 689 citations

, , +17

Immunotherapy Against HPV16/18 Generates Potent T <sub>H</sub> 1 and Cytotoxic Cellular Immune Responses

Mark L. Bagarazzi, Jian Yan, Matthew P. Morrow et al. · Science Translational Medicine · 2012 · 279 citations · Full text

A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

Kar Muthumani, Darryl Falzarano, Emma L. Reuschel et al. · Science Translational Medicine · 2015 · 249 citations · Full text

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

Spyros A. Kalams, Scott Parker, Marnie Elizaga et al. · The Journal of Infectious Diseases · 2013 · 193 citations · Full text

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

Mark Yarchoan, Edward Gane, Thomas U. Marron et al. · Nature Medicine · 2024 · 177 citations · Full text

Rows per page

1–5 of 111